People: Atara Biotherapeutics Inc (ATRA.OQ)
17 Sep 2019
Dr. Dietmar Berger is Global Head of Research and Development of the Company. He has served as Global Head of Research and Development since May 2018. Prior to joining Atara, from November 2011 to March 2018, Dr. Berger worked at Genentech, Inc. a Member of the Roche Group and was most recently the Senior Vice President and Global Head, Product Development, Clinical Science Hematology and Oncology. From October 2009 to November 2011, he led oncology clinical development at Bayer, and from February 1999 to October 2009 held positions of increasing responsibility at Amgen. He received the Cancer Award of the German Cancer Society for his research on angiogenesis and earned his M.D. and Ph.D. degrees from the University of Freiburg.
|Total Annual Compensation, USD||748,152|
|Restricted Stock Award, USD||2,102,500|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||2,121,790|
|Fiscal Year Total, USD||4,972,440|